COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN DOMINICAN REPUBLIC, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL

被引：0
|
作者：
Obando, C. A. [1 ]
Desanvicente-Celis, Z. [1 ]
Gonzalez, L. [2 ]
Muschett, D. [1 ]
Gonzalez, F. [1 ]
Goldberg, P. [1 ]
机构：
[1] Janssen, Panama City, Panama
[2] Janssen, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN121
引用
收藏
页码：A635 / A635
页数：1
相关论文
共 50 条
  • [21] Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction
    Cindolo, Luca
    Natoli, Clara
    De Nunzio, Cosimo
    De Tursi, Michele
    Valeriani, Maurizio
    Giacinti, Silvana
    Micali, Salvatore
    Rizzo, Mino
    Bianchi, Giampaolo
    Martorana, Eugenio
    Scarcia, Marcello
    Ludovico, Giuseppe Mario
    Bove, Pierluigi
    Laudisi, Anastasia
    Selvaggio, Oscar
    Carrieri, Giuseppe
    Bada, Maida
    Castellan, Pietro
    Topazio, Luca
    Boccasile, Stefano
    Ditonno, Pasquale
    Chiodini, Paolo
    Schips, Luigi
    CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : 520 - 525
  • [22] COST-EFFECTIVENESS EVALUATION OF ENZALUTAMIDE AND ABIRATERONE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PROGRESSING AFTER DOCETAXEL IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM
    Gay, J. G.
    Schultz, N. M.
    Braun, S.
    VALUE IN HEALTH, 2018, 21 : S29 - S30
  • [23] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    M. Koninckx
    J. L. Marco
    I. Pérez
    M. T. Faus
    V. Alcolea
    F. Gómez
    Clinical and Translational Oncology, 2019, 21 : 314 - 323
  • [24] A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer
    Clayton, Ravinder
    Wu, Jackson
    Heng, Daniel Y.
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien
    Chi, Kim
    Zielinski, Rob
    Al-Shamsi, Humaid
    Chen, Leo
    Eigl, Bernhard
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (9-10): : E583 - E590
  • [25] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    Koninckx, M.
    Marco, J. L.
    Perez, I.
    Faus, M. T.
    Alcolea, V.
    Gomez, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (03): : 314 - 323
  • [26] Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
    Zhong, Lixian
    Pon, Vickie
    Srinivas, Sandy
    Nguyen, Nicole
    Frear, Meghan
    Kwon, Sherry
    Gong, Cynthia
    Malmstrom, Robert
    Wilson, Leslie
    PLOS ONE, 2013, 8 (05):
  • [27] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [28] The docetaxel-abiraterone acetate sequence compared to the abiraterone acetate-docetaxel sequence in metastatic castration-resistant prostate cancer patients with a response to previous castration superior to 12 months.
    Desle, Maxime
    Derminne, Alexandre
    Lejeune, Sarah
    Seront, Emmanuel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [30] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
12345